About IN8bio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.in8bio.com
Frequently Asked Questions
What is the 52-week range for INAB?
The 52-week high is $2.73 and the 52-week low is $0.88.
What is the P/E ratio for INAB?
The P/E ratio data is currently unavailable.
What is the dividend yield for INAB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -91.18%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.39.
Analyst Recommendation Trends
Wall Street analyst consensus for INAB over the last few months:
Latest INAB News
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York. Mr. Ho and members of the IN8bio management team will
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | -724,637 | - | - |
| 2026-05-09 | Graff Jeremy R. | +22,000 | - | - |
| 2026-05-09 | Rochlin Kate | +60,000 | - | - |
| 2026-05-09 | McCall Patrick | +56,250 | - | - |
| 2026-05-09 | Greenwood Luba | +22,000 | - | - |
| 2026-05-09 | Epperly Corinne | +22,000 | - | - |
| 2026-05-09 | Ho William Tai-Wei | +154,500 | - | - |
| 2026-05-09 | Lamb Lawrence | +54,000 | - | - |
| 2026-05-09 | FAIRBAIRN EMILY | +22,000 | - | - |
| 2026-05-09 | Brandt Peter C. | +22,000 | - | - |
| 2026-02-04 | Rochlin Kate | +80,000 | - | - |
| 2026-02-04 | McCall Patrick | +75,000 | - | - |
| 2026-02-04 | Ho William Tai-Wei | +206,000 | - | - |
| 2026-02-04 | Lamb Lawrence | +72,000 | - | - |
| 2025-12-22 | Rochlin Kate | +7,247 | $1.38 | $10,001 |
| 2025-12-22 | McCall Patrick | +7,247 | $1.38 | $10,001 |
| 2025-12-22 | Ho William Tai-Wei | +36,232 | $1.38 | $50,000 |
| 2025-12-22 | FAIRBAIRN EMILY | +724,637 | $1.38 | $999,999 |
| 2025-12-22 | Roemer Alan S. | +36,232 | $1.38 | $50,000 |
| 2025-12-22 | Brandt Peter C. | +72,464 | $1.38 | $100,000 |